Navigation Links
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
Date:6/1/2009

- Results Presented at American Society of Clinical Oncology (ASCO) Meeting Show Fleximer(R) Conjugated Drug Is Well Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors -

CAMBRIDGE, Mass., June 1 /PRNewswire/ -- Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is a broad-spectrum cytotoxic, based on camptothecin (CPT), conjugated to Mersana's biodegradable polymer platform, Fleximer(R).

Ten of 37 evaluable patients dosed to date demonstrated evidence of stable disease and seven patients had prolonged stable disease for at least 12 weeks. The study has also demonstrated that XMT-1001 can be safely given to patients. Toxicities such as hemorrhagic cystitis and serious diarrhea were not observed in this preliminary assessment. In addition, a favorable pharmacokinetic profile was observed. Full text of the abstract can be viewed online at the ASCO website at www.abstract.asco.org.

"We are encouraged by the favorable safety and pharmacokinetic profile demonstrated by XMT-1001 thus far," said Julie Olson, Chief Executive Officer of Mersana. "These preliminary results build on our preclinical studies, which showed that XMT-1001 has greater efficacy in human tumor xenograft models than comparable doses of irinotecan, an agent with a similar mechanism of action as camptothecin and that is approved to treat patients with colon cancer. We look forward to advancing XMT-1001 into a Phase 2 trial in a solid tumor indication."

About the XMT-1001 Preliminary Study

The Phase 1 trial is an open label, dose escalation study of XMT-1001 administered as an IV infusion once every three weeks in pat
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
2. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... What and When, Additional results from the ... pioGlitazOne) published,today in Circulation revealed that reduced progression ... was,associated with increased levels of HDL cholesterol (HDL-C, ... increased effect on HDL-C levels at 24 weeks ...
... April 15 Pacira Pharmaceuticals, Inc. today,announced ... the,development of sustained release injectable products based ... companies will work,together to enhance the dosing ... development pipeline. The goal of the collaboration ...
... Inc.,(Nasdaq: BNVI ) will present findings on the ... and BN108 at the American Association of,Cancer Research (AACR) ... San,Diego, CA, April 12 - 16, 2008., Bionovo,s ... (cell death) induced by BN107 and BN108. As explained ...
Cached Biology Technology:New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 2New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl) 3Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R) 2Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research 2
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... do some microorganisms manage to exist and even thrive ... A team of scientists from the Weizmann Institute's Plant ... that a switch in just two amino acids (the ... functioning best at moderate temperatures and being adapted to ...
... 20 and older has risen from about 5.1 percent to ... Health (NIH) and the Centers for Disease Control and Prevention ... 1994 and 1999 to 2002. However, the percentage of ... years studied. About 2.8 percent of U.S. adult--one-third of ...
... Lauren Gerson, MD, so overjoyed are they at hearing her ... eat chocolate. Indulge your passion for spicy cuisine. Drink red ... juice with breakfast and, what the heck, eat a grapefruit, ... evidence to support the notion that eating these foods will ...
Cached Biology News:Bacteria beat the heat 2One-third of adults with diabetes still don't know they have it 2One-third of adults with diabetes still don't know they have it 3One-third of adults with diabetes still don't know they have it 4Chocolate, wine, spicy foods may be OK for heartburn, Stanford study finds 2Chocolate, wine, spicy foods may be OK for heartburn, Stanford study finds 3Chocolate, wine, spicy foods may be OK for heartburn, Stanford study finds 4
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
...
... perfusion system for small volumes of ... or general liquid-handling research applications. ... microliters of precious drugs. Switch between ... from a single tip. Minimize ...
Biology Products: